Skip to main content
NewslettersWatchlist

Moderna Inc(MRNA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low35.96
Day High38.82
Open:36.55
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stocks Settle Mostly Higher on Tech Stock Strength and Lower Bond Yields
Barchart
Stocks Mostly Higher on Positive Corporate News
Barchart
Option Volatility And Earnings Report For November 18 - 22
MarketBeat
Deciphering Disruption: Inside Cathie Wood's Latest Plays
Baystreet
Profit-Taking Marks Friday
Barchart
Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts
Barchart
Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields
Barchart
Stocks Retreat as Bond Yields Climb on a Hawkish Fed
Barchart
Option Volatility And Earnings Report For November 11 - 15
Motley Fool
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Barchart
Stocks Finish Higher as Fed Cuts Interest Rates
Motley Fool
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Barchart
Stocks Supported by Speculation Trump’s Policies to Boost Corporate Profits
Barchart
Stocks Extend Post-Election Gains Ahead of the FOMC Meeting
Motley Fool
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
Motley Fool
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
The Globe and Mail
Pfizer struggles to find new revenue sources as vaccine sales fade, but here’s why investors shouldn’t shy away from its stock
Barchart
Option Volatility And Earnings Report For November 4 - 8
Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Barchart
Stocks Close Higher on Reduced Middle East Risks
Barchart
Stocks Higher on Relief After Israel's Limited Retaliation Reduces Middle East Risks
Motley Fool
How Bad Is This News for Novavax?

Profile

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.